Christopher Richard Anzalone Sells 13,187 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 13,187 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the transaction, the chief executive officer owned 3,792,739 shares of the company’s stock, valued at approximately $250,700,047.90. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 29th, Christopher Richard Anzalone sold 51,726 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $69.13, for a total transaction of $3,575,818.38.
• On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.44, for a total value of $861,385.84.
• On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $67.66, for a total value of $909,688.70.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $64.04, for a total value of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $62.58, for a total transaction of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00.

Arrowhead Pharmaceuticals Trading Down 5.8%

Shares of ARWR traded down $3.91 during mid-day trading on Monday, hitting $63.88. The company had a trading volume of 2,692,485 shares, compared to its average volume of 2,131,468. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $72.36. The stock has a market cap of $8.68 billion, a PE ratio of -798.40 and a beta of 1.21. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The business’s 50-day simple moving average is $55.20 and its 200-day simple moving average is $35.35.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in Arrowhead Pharmaceuticals during the second quarter valued at about $576,000. Marshall Wace LLP raised its position in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the last quarter. Moody Lynn & Lieberson LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $213,000. HBK Sorce Advisory LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $2,823,000. Finally, Norges Bank acquired a new stake in Arrowhead Pharmaceuticals during the second quarter worth $30,414,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of several recent analyst reports. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. HC Wainwright boosted their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 26th. The Goldman Sachs Group boosted their price objective on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Finally, Bank of America raised their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.89.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.